In the first half of 2026, 61% of reimbursed drug costs were allocated to cardiovascular medications, while 15% were for anti-diabetic drugs.
This was reported by the Universal Health Insurance Fund.
This distribution indicates that a significant portion of drug reimbursements is directed towards ensuring the continuous treatment of widely prevalent chronic diseases.
